Canopy Growth Corp

CGC

1.380USD

+0.020+1.47%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

117 / 175

Overall Ranking

344 / 4723

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Hold

Current Rating

3.650

Target Price

+151.72%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.

Undervalued

The company’s latest PE is -0.24, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 16.44M shares, decreasing 19.56% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.73.

The company's current financial score is 7.12, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 53.01M, representing a year-over-year increase of 9.50%, while its net profit experienced a year-over-year increase of 132.83%.

Score

Industry at a Glance

Previous score

7.56

Change

-0.44



Financials

6.29

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.62

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.85

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.67

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.19

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -0.24, which is -59.89% below the recent high of -0.10 and 4.21% above the recent low of -0.23.

Score

Industry at a Glance

Previous score

1.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 117/175

No Data

The company’s current earnings forecast score is 6.00, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Canopy Growth Corp is 3.65, with a high of 3.65 and a low of 3.65.

Score

Industry at a Glance

Previous score

6.00

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 4.80, which is lower than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 1.81 and the support level at 1.03, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.25

Change

-0.45

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-17

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Tidal Investments LLC

3.83M

+69.15%

Global X Investments Canada Inc.

1.17M

-0.37%

Susquehanna International Group, LLP

1.10M

+188.30%

Millennium Management LLC

1.84M

+243.22%

Goldman Sachs & Company, Inc.

282.55K

+84.93%

Morgan Stanley Canada Limited

466.04K

+54.22%

SBI Securities Co., Ltd.

360.74K

+68.37%

Jane Street Capital, L.L.C.

850.57K

+81.67%



1

2



The company’s current risk assessment score is 2.99, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 2.37. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Canopy Growth Corp

CGC

4.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.88 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.76 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Supernus Pharmaceuticals Inc

SUPN

7.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

7.69 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

7.67 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment